Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2014 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (224)	1/24/2014 6:46:30 PM
From: rkrw	Read Replies (1) \| Respond to of 487

Amazing how fast you are with the reports........when you're in the lead :)

To: BulbaMan who wrote (224)	1/24/2014 6:47:19 PM
From: IRWIN JAMES FRANKEL	Respond to of 487

You could start your own hedge fund or maybe get a job one. :-)

To: BulbaMan who wrote (224)	1/25/2014 9:31:37 PM
From: N. Dixon	Respond to of 487

“Emperor of all Maladies.” An absolute "must read"--- especially the history of breast cancer treatment. You can get it on audible and listen to it. That's how I did it. Listened while working out. ND

To: BulbaMan who wrote (224)	1/28/2014 4:47:40 PM
From: technetium	Read Replies (1) \| Respond to of 487

Capricor, my zodiac killer of a stock, has thrust my portfolio to first place with a mind-boggling 54.17% YTD gain! It's especially mind-boggling given that it is still January. At this rate, you'll have $3,000,000 in August and you can take a nice summer vacation! :-) BTW, astrological signs are used for almost everything from perfumes to cars, but the one sign that gets left behind is Cancer.

To: BulbaMan who wrote (224)	1/31/2014 7:06:30 PM
From: BulbaMan	Read Replies (1) \| Respond to of 487

1/31/14 Contest update For the S&P 500, it was the first January loss since 2010. But despite a bit of harassment by the Bears, biotechs managed to finish the month in positive territory. At Friday’s close, the Contest median was up 16.10% YTD (vs. up 17.54% YTD a week ago), while the Nasdaq Biotech Index actually held its ground, finishing the week up 8.41% YTD (vs. up 7.64% YTD a week ago). However, the Nasdaq Composite Index closed down -1.74% YTD (vs. down -1.16% YTD a week ago). Although my own portfolio did get clawed back, it still held the Contest lead with 44.75% YTD gain. JB118’s portfolio, up 30.79% YTD, took second place, with ROCKY's portfolio, up 30.66% YTD, behind by a hair in third place. At Friday's close, all 46 Contest portfolios continued in the black but a mere 39 of the 46 were now beating the NBI. Below is the Top Ten list. Also below are the Top 5 & Bottom 5 Stocks ranked by % Gained and % Lost for the week. Portfolio adjustments: none (All corrections, especially adjustments for splits, greatly appreciated.) Have a concussion-free Super Bowl weekend biotechies! Peace & good health, Bulba 1/31/14 Rank Name Profit/Loss 1 BULBA 44,747 2 JB118 30,785 3 ROCKY 30,658 4 BIOINV 29,762 5 GUERL 28,809 6 ROBERT 27,664 7 GENE 26,928 8 SCARAM 26,475 9 DOUGH 25,581 10 MCBIO 23,658 Week's Top 5 Gainers Symbol 1/17 1/31 Wk.%chg. ARWR 11.72 15.34 30.89% PRAN 8.99 11.60 29.03% ENTA 30.03 36.58 21.81% MRNA 0.74 0.89 21.09% PRTA 25.95 30.94 19.23% Week's Worst 5 Losers Symbol 1/17 1/31 Wk.%chg. KBIO 5.32 3.120 -41.35% PGNX 6.37 4.780 -24.96% ITMN 16.85 13.350 -20.77% FPRX 18.46 14.660 -20.59% CTIC 4.00 3.190 -20.25%